<DOC>
	<DOCNO>NCT02051049</DOCNO>
	<brief_summary>The purpose study ass long-term safety follow-up patient treated HepaStem .</brief_summary>
	<brief_title>Long-term Safety Follow-up Study Patients Having Received HepaStem ( SAF001 )</brief_title>
	<detailed_description>The primary objective SAF001 study long-term safety surveillance patient post infusion HepaStem . Furthermore , evolution metabolic condition quality life follow . As much possible , surveillance mimic standard follow-up respective disease ( standard care ) . The surveillance end patient undergo organ transplant take part another research study . This surveillance last maximum 48 month .</detailed_description>
	<mesh_term>Urea Cycle Disorders , Inborn</mesh_term>
	<mesh_term>Crigler-Najjar Syndrome</mesh_term>
	<criteria>Main Subject receive HepaStem former interventional clinical study terminate participation study . Subject receive mature liver cell , stem cell transplantation HepaStem , organ liver transplant .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>23 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>CN</keyword>
	<keyword>UCD</keyword>
</DOC>